,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'bcsm']
#asco22 journals getting more enthusiastic and efficient with concurrent publications. now destiny-04 #bcsm #her2 overall survival was 23.4 months and 16.8 months. will see how it translates to other tumor types. #her2 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22